Methodology
Understanding how VIALLMED HUB ranks pharmaceutical products using advanced CPI ratings and data-driven analytics.
CPI Rating System Overview
The CPI (Clinical Preference Index) rating system has been adapted by VIALLMED HUB to provide objective, quantitative assessments of pharmaceutical product performance. Unlike traditional ranking methods that rely on single metrics, our multi-factorial CPI approach captures the complexity of drug performance across clinical, regulatory, and market dimensions.
Each drug starts with a base CPI rating that adjusts dynamically based on performance across multiple factors. Higher-rated drugs have demonstrated superior performance in clinical trials, regulatory approvals, market adoption, and professional sentiment.
Ranking Factors
Six key dimensions evaluated and weighted to produce each drug's final CPI score.
Success rates across Phase I, II, and III clinical trials. Higher success rates indicate robust efficacy and safety profiles, significantly boosting CPI ratings.
Regulatory approval success and timeline efficiency. Drugs with faster, smoother approval processes demonstrate regulatory confidence and market readiness.
Market adoption measured by prescription rates and volume rankings. High prescription volume reflects real-world physician confidence and patient access.
Short-term and long-term performance changes tracked across 24h, 7d, 30d, and annual periods. Consistent positive trends indicate sustained market strength.
Healthcare provider opinions measured through bullish/bearish voting. Professional sentiment provides qualitative insights into prescribing confidence.
Long-term track record and consistency. Established drugs with proven histories receive stability bonuses, while new entrants are evaluated on potential.
Calculation Process
Four sequential stages that transform raw pharmaceutical data into a precise CPI score.
Pharmaceutical data is aggregated from multiple verified sources including clinical trial databases, FDA publications, prescription tracking systems, and healthcare provider networks. All data undergoes validation and quality checks before integration.
Each ranking factor is weighted based on its predictive value for drug success. Clinical trial success and FDA approval rates receive the highest weights, followed by market metrics and sentiment indicators. Weights are calibrated using historical data and industry expertise.
Weighted factors are combined using our proprietary CPI algorithm to generate a single comprehensive rating. The algorithm accounts for factor interactions and normalizes scores across therapeutic areas to enable fair comparisons.
Rankings are updated in real-time as new data becomes available. The system processes updates hourly for market metrics and daily for clinical/regulatory data, ensuring rankings reflect current performance.
Interpreting Rankings
VIALLMED HUB CPI ratings provide a standardized measure of pharmaceutical product performance.
Top-tier drugs with exceptional clinical outcomes, regulatory success, and market dominance. These products represent industry gold standards.
High-performing drugs with proven efficacy and substantial market presence. Solid clinical profiles and consistent market growth.
Competent drugs with acceptable clinical and market metrics. May excel in specific areas while showing moderate performance in others.
Early-stage products or drugs with limited track records. May include new market entrants or products facing challenges in clinical or market performance.
Limitations & Disclaimers
Important context for properly interpreting VIALLMED HUB data.
VIALLMED HUB rankings are for informational and analytical purposes only. They should not be construed as medical advice, treatment recommendations, or endorsements of specific pharmaceutical products.
While we implement rigorous quality controls, we cannot guarantee 100% accuracy of all data. Users should independently verify critical information before making significant business or clinical decisions.
Rankings reflect current and historical performance. Past performance does not guarantee future results, especially in the dynamic pharmaceutical industry.
Rankings enable relative comparisons within therapeutic areas and across the industry. However, drugs addressing different conditions should be evaluated in their specific clinical contexts.